PALO ALTO, Calif., Aug. 4 CA-Anacor-New-VP
PALO ALTO, Calif., Aug. 4 /PRNewswire/ -- Anacor Pharmaceuticals announced
today that it has appointed Kurt Jarnagin, Ph.D., as its Vice President of
Biological Research.
"We are pleased to welcome Kurt to the company," said Jacob Plattner,
Ph.D., Senior Vice President of Research at Anacor Pharmaceuticals. "Kurt is a
noted expert in the field of small molecule drugs involved in inflammation and
his expertise will enrich our team as we continue to expand our pipeline fed
by our boron chemistry platform."
Previously, Dr. Jarnagin was with Iconix Pharmaceuticals, Inc., serving as
Vice President of Biology and Chemogenomics and Vice President of New
Technology and Translational Medicine from 1998 to 2007. Dr. Jarnagin also
held research leadership roles at Roche Pharmaceuticals (Palo Alto) from 1994
to 1998 and at Syntex Research, a specialty pharmaceutical company acquired by
Roche, from 1986 to 1994.
At Iconix he directed the development of the DrugMatrix and ToxFX
products -- tools and decision-making resources that aid scientists in the
selection and prioritization of novel drugs. At Roche and Syntex he focused
on drug discovery, targeting receptors and enzymes involved in inflammation,
arthritis and asthma. Dr. Jarnagin was awarded the Fry-E. Werele
International Kinin Chemistry Prize for work in the bradykinin field. He is
the author of numerous peer-reviewed scientific papers and has several granted
patents.
Dr. Jarnagin carried out highly cited studies of the insulin receptor at
the Hormone Research Institute of the University of California, San Francisco.
He received his Ph.D. in Biochemistry from the University of Wisconsin,
Madison, and holds a B.S. in Biochemistry from North Carolina State University
in Raleigh.
About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company developing novel small molecule
therapeutics derived from its boron chemistry platform. Anacor has focused
initially on developing topical applications of its compounds to treat fungal,
bacterial and inflammatory diseases. Anacor's most advanced product candidate
is AN2690, a novel topical antifungal in development for the treatment of
toenail onychomycosis, which is a fungal infection of the nail and nail bed.
AN2690 is licensed to Schering-Plough under a worldwide development and
commercialization agreement for all indications including the treatment of
onychomycosis. Anacor also has a research and development collaboration with
GlaxoSmithKline for the discovery, development, manufacture and worldwide
commercialization of novel systemic therapeutics for viral and bacterial
diseases utilizing Anacor's boron-based chemistry. For more information visit
http://www.anacor.com.
SOURCE Anacor Pharmaceuticals
